Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis

Ricky D. Turgeon¹, Michael R. Kolber², Peter Loewen³, Ursula Ellis⁴, James P. McCormack⁵*

¹ Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada, ² Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada, ³ Faculty of Pharmaceutical Sciences, Collaboration for Outcomes Research & Evaluation, University of British Columbia, Vancouver, British Columbia, Canada, ⁴ Woodward Library, University of British Columbia, Vancouver, British Columbia, Canada, ⁵ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada

* james.mccormack@ubc.ca

Abstract

Background

Current heart failure (HF) guidelines recommend titrating angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and beta-blockers (BBs) to target doses used in pivotal placebo-controlled randomized controlled trials (RCTs). Despite a number of RCTs comparing different doses (i.e. higher versus lower doses) of ACEIs, ARBs and BBs, the effects of higher versus lower doses on efficacy and safety remains unclear. For this reason, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of higher versus lower doses of ACEIs, ARBs and BBs in patients with HFrEF.

Methods

We searched MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) via Ovid from inception to April 25th, 2018 and opentrials.net and clinicaltrials.gov for relevant trials that compared different doses of medications in heart failure. We analyzed trials by drug class (ACEIs, ARBs, and BBs) for efficacy outcomes (all-cause mortality, cardiovascular mortality, all-cause hospitalizations, HF hospitalizations, HF worsening). For safety outcomes, we pooled trials within and across drug classes.

Results

Our meta-analysis consisted of 14 RCTs. Using GRADE criteria, the quality of evidence for ACEIs and ARBs was assessed as generally moderate for efficacy and high for adverse effects, whereas overall quality for BBs was very low to low. Over ~2–4 years higher versus lower doses of ACEIs, ARBs or BBs did not significantly reduce all-cause mortality [ACEIs
relative risk (RR) 0.94 (95% confidence interval 0.87–1.02), ARBs RR 0.96 (0.87–1.04), BBs RR 0.25 (0.06–1.01) or all cause hospitalizations [ACEIs relative risk (RR) 0.94 (95% confidence interval 0.86–1.02), ARBs RR 0.98 (0.93–1.04), BBs RR 0.93 (0.39–2.24)]. However, all point estimates favoured higher doses. Higher doses of ARBs significantly reduced hospitalization for HF [RR 0.89 (0.80–0.99)– 2.8% ARR], and higher doses of ACEIs and ARBs significantly reduced HF worsening [RR 0.85 (0.79–0.92)– 5.1% ARR and 0.91 (0.84–0.99)– 3.2% ARR, respectively] compared to lower doses. None of the differences between higher versus lower doses of BBs were significant; however, precision was low. Higher doses of these medications compared to lower doses increased the risk of discontinuation due to adverse events, hypotension, dizziness, and for ACEIs and ARBs, increased hyperkalemia and elevations in serum creatinine. Absolute increase in harms for adverse effects ranged from ~ 3 to 14%.

**Conclusions**

Higher doses of ACEIs and ARBs reduce the risk of HF worsening compared to lower doses, and higher doses of ARBs also reduce the risk of HF hospitalization but the evidence is sparse and imprecise. Higher doses increase the chance of adverse effects compared to lower doses. Evidence for BBs is inconclusive. These results support initially always starting at low doses of ACEIs/ARBs and only titrating the dose up if the patient tolerates dose increases.

**Introduction**

Heart failure (HF) with reduced ejection fraction (HFrEF) is a prevalent condition with an overall poor prognosis.[1] The combination of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-2 receptor blocker (ARB) plus a beta-blocker (BB) is first-line therapy for HFrEF management,[1],[2] as these medications reduce morbidity and mortality compared to placebo.[3],[4],[5] These results have led guideline authors to universally recommend starting these agents in most patients with (HFrEF).[1],[2]

The approach recommended by guidelines when initiating these medications is to start at a low-to-moderate dose and titrate as tolerated to the target doses used in placebo-controlled randomized controlled trials (RCTs).[1],[2] However, many patients are unable to achieve and maintain target doses due to adverse effects, with most patients only achieving ~50% of the target dose.[6] Despite a number of RCTs comparing different doses (i.e. higher versus lower doses) of ACEIs, ARBs and BBs, the effects of higher versus lower doses on efficacy and safety remains unclear. For this reason, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of higher versus lower doses of ACEIs, ARBs and BBs in patients with HFrEF.

**Methods**

**Design**

Systematic review with meta-analysis in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement.[7]
Search strategy

We searched MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) via Ovid from inception to April 25th, 2018 using keywords and subject headings for the following concepts: heart failure, ACEI, ARB, BB, dose, and randomized controlled trial (see S1 Appendix for MEDLINE search strategy). We also searched opentrials.net and clinicaltrials.gov for relevant RCTs, and hand-searched bibliographies of included studies.

Eligibility criteria and outcomes

We included parallel RCTs published in English evaluating different doses of the same drug within the class of ACEIs, ARBs, or BBs in patients with HFrEF as defined by study investigators. Eligible trials needed to report results for at least one of the following outcomes: all-cause mortality, cardiovascular mortality, all-cause hospitalizations, HF hospitalizations, HF worsening, serious adverse events, discontinuation due to adverse events, hypotension, lightheadedness/dizziness, hyperkalemia, renal dysfunction, and cough. While there is evidence some of these drug classes have dose-related hemodynamic and neurohormonal effects, we chose to only include trials whose clinical outcomes would likely be relevant to clinicians and patients.

Study selection and data collection

Three authors (MK, PL, JM) screened candidate articles for inclusion, identified missing data, and consulted original publications. The same authors individually extracted crude outcome data from full-text reports into a standardized database. For trials comparing >2 doses, we included the results from only the lowest and highest dose arms, hereafter referred to as “higher dose” and “lower dose”. Discrepancies and missing data were resolved by group discussion, reference to the original publication, and additional independent adjudication by all authors.

Risk of bias and quality of evidence assessment

Two authors (JM, PL) assessed individual trials for risk of bias using the Cochrane Collaboration Risk of Bias Tool.[8] For each trial, we classified trials as being at low, high, or unclear risk of bias in each of 5 domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors and incomplete outcome data. Disagreements were resolved by consensus with a third author (RT). We also rated the quality of evidence for individual outcomes from high to very low based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which incorporates risk of bias, consistency, directness, precision, and other considerations.[9]

Synthesis of results and assessment of heterogeneity

We performed all analyses using Review Manager 5.3 (Cochrane Collaboration). We pooled trials by drug class studied at the study level and calculated risk ratios (RRs) with 95% confidence intervals (CIs), and absolute risk difference per 1000 patients treated over the follow-up period. For efficacy outcomes, we analyzed trials by drug class (ACEIs, ARBs, and BBs). For safety outcomes, we pooled trials within and across drug classes. All comparisons used high dose as the experimental intervention and low dose as the control intervention. We evaluated for statistical heterogeneity by visually inspecting forest plots and by calculating the $I^2$ statistic. For efficacy outcomes, we reported fixed-effects model results for analyses with $I^2<50\%$ and the random-effects model results for an $I^2\geq50\%$. We reported all safety outcomes using fixed-effects models to minimize type 2 error.
Results

Included studies

From 1923 articles identified, we included 14 RCTs with sample size ranging from 83 to 3846 participants (Fig 1). We identified evidence for the following interventions: ACEIs (7 studies, n = 5,817),[10],[11],[12],[13],[14],[15],[16] ARBs (3 studies, n = 4,908),[17],[18],[19] and BBs (4 studies, n = 1,018).[20],[21],[22],[23]

Characteristics of included trials

Table 1 summarizes key characteristics of the included trials. At baseline, the mean age across trials ranged from 54–70 years, approximately 75% of participants were male, and the majority

Fig 1. PRISMA flow diagram.

https://doi.org/10.1371/journal.pone.0212907.g001
had NYHA functional class 2 or 3 symptoms. Twelve trials required reduced ejection fraction (EF) at baseline, ranging from <30% to <50%. Eight trials compared >2 doses; seven studies (50%) compared a 4-fold increase in dose (between the groups receiving the lowest and highest dose), 4 studies (29%) compared 7 to 16-fold differences in doses, and three studies (21%) compared a 2 to 3-fold difference in dose. The weighted mean follow-up duration across included studies was 34 months (ACEIs 28 months, ARBs 45 months, BBs 17 months). Three studies that accounted for 63% of patients in this meta-analysis had follow-up greater than 12 months.[10],[18],[21]

### Risk of bias and quality assessment

All trials except the HEAAL study had high or unclear risk of bias in at least 3 of the 5 domains (Fig 2). Quality of evidence for ACEIs and ARBs was generally moderate for efficacy and high

---

**Table 1. Characteristics of included trials.**

| Trial (year) | n  | Follow-up duration, months | Mean age, y | Male, % | NYHA class, % | LVEF, % | ACEI or ARB | BB | MRA | Digoxin | Drug | Higher dose, mg/day | Lower dose, mg/day | Ratio |
|-------------|----|-----------------------------|-------------|--------|---------------|--------|-------------|----|-----|---------|------|-------------------|-------------------|-------|
| ACEIs       |    |                             |             |        |               |        |             |    |     |         |      |                   |                   |       |
| ATLAS (1999)| 3164| Mean 46 (range 39–58)       | 64          | 80     | 16            | 70     | <30         | 23 | 89  | NR      | NR   | Lisinopril 32.5 to 35 | 2.5 to 5          | 7–13 |
| NETWORK (1998)| 1532| 6                           | 70          | 64     | 65            | 33     | 2           | None | 20a | NR    | NR   | Enalapril 20         | 5                 | 4     |
| CHIPS (2000)| 298 | 12                          | 65          | 69     | 38            | 50     | 0           | <45 | NR  | NR    | 26   | Captopril 100        | 50                | 2     |
| HEDS (2000)| 248 | 12                          | 56          | 85     | 42            | 44     | 11          | <35 | 20  | NR    | NR   | Enalapril 60         | 20                | 3     |
| CASSIS (1995)| 248 | 3                           | 58          | 83     | 25            | 56     | 19          | <40 | 28  | 5      | NR   | Spirapril 6          | 1.5               | 4     |
| van Veldhuisen (1998)| 244 | 3                           | 61          | 77     | 77            | 23     | 0           | <45 | 34  | NR    | NR   | Imidapril 10        | 2.5               | 4     |
| Pacher (1996)| 83  | 11                          | 56          | 83     | 2             | 80     | 18          | None | NR  | 100   | NR   | Enalapril 40        | 10                | 4     |
| ARBs        |    |                             |             |        |               |        |             |    |     |         |      |                   |                   |       |
| HEAAL (2009)| 3846| Mean 56 (IQR 41–66)         | 66          | 71     | 69            | 30     | 1           | <40 | 33  | NR    | 72   | Losartan 150        | 50                | 3     |
| STRETCH (1999)| 844 | 3                           | 62          | 68     | 81            | 19     | 0           | 30–40 | 39   | 59     | NR   | Candesartan 16      | 4                 | 4     |
| Havranek (1999)| 218 | 3                           | 60          | 82     | 63            | 21     | 16          | <40 | 24  | NR    | NR   | Irbesartan 150      | 12.5              | 12    |
| BBs         |    |                             |             |        |               |        |             |    |     |         |      |                   |                   |       |
| J-CHF (2013)| 360 | Mean 36                     | 60          | 74     | 83            | 17     | 0           | <40 | 30  | 87     | NR   | Carvedilol 20       | 2.5               | 8     |
| MOCHA (1996)| 345 | 6                           | 60          | 76     | 46            | 52     | 2           | <35 | 23  | 94     | NR   | Carvedilol 50       | 12.5              | 4     |
| MUCHA (2004)| 174 | 6–12                        | 60          | 78     | 79            | 21     | 0           | <40 | 30  | 76     | NR   | Carvedilol 20       | 5                 | 4     |
| Bristow (1994)| 139 | 3                           | 54          | 61     | 42            | 55     | 0           | <40 | 24  | 87     | NR   | Bucindolol 200      | 12.5              | 16    |

ACEI: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin-2 receptor blocker, BB: beta-blocker, IQR: Interquartile range, LVEF: Left ventricular ejection fraction, MRA: Mineralocorticoid receptor antagonist, NR: Not reported.

*a Estimated from mean baseline left ventricular end-diastolic (LVEDD) and end-systolic dimensions (LVESD) using the equation LVEF = (LVEDD-LVESD) / LVEDD

https://doi.org/10.1371/journal.pone.0212907.t001
### Fig 2. Risk of bias summary.

| Study                              | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) |
|------------------------------------|---------------------------------------------|----------------------------------------|---------------------------------------------------------|-------------------------------------------------|----------------------------------------|
| Bristow 1994                       | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Bristow 1996 (MOCHA)               | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Clement 2000 (CHIPS)               | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Havranek 1999                      | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Hori 2004 (MUCHA)                  | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Konstam 2009 (HEAAL)               | +                                           | +                                      | +                                                       | +                                               | +                                      |
| Nanas 2000 (HEDS)                  | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Okamoto 2013 (J-CHF)               | +                                           | ?                                      | ?                                                       | ?                                               | ?                                      |
| Pacher 1996                        | +                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Packer 1999 (ATLAS)                | ?                                           | ?                                      | ?                                                       | Question mark                                   | ?                                      |
| Poole-Wilson 1998 (NETWORK)        | ?                                           | ?                                      | ?                                                       | ?                                               | ?                                      |
| Rieger 1999 (STRETCH)              | +                                           | ?                                      | ?                                                       | ?                                               | ?                                      |
| van Veldhuisen 1998                | ?                                           | ?                                      | ?                                                       | ?                                               | -                                      |
| Widinsky 1995 (CASSIS)             | ?                                           | ?                                      | ?                                                       | ?                                               | +                                      |

https://doi.org/10.1371/journal.pone.0212907.g002
Table 2. GRADE summary of findings. Statistically significant results are shown in bold text.

| Outcome                          | ACEIs                  | ARBs                  | BBs                  |
|----------------------------------|------------------------|-----------------------|----------------------|
|                                  | Quality of evidence    | Effect (follow-up range 3–58 months–mean 28 months) | Certain assessment | Effect (follow-up range 3–66 months–mean 45 months) | Certain assessment | Effect (follow-up range 3–36 months–mean 17 months) |
|                                  | RR (95% CI)            | Absolute change, per 1000 | RR (95% CI)           | Absolute change, per 1000 | RR (95% CI)           | Absolute change, per 1000 |
| Mortality                        |                        |                       |                      |                         |                       |                        |
| All-cause                        | MODERATE 1             | 0.94 (0.87 to 1.02)   | 19 fewer (from 6 more to 40 fewer) | MODERATE 1             | 0.96 (0.87 to 1.04)   | 12 fewer (from 12 more to 40 fewer) | LOW 2                 | 0.25 (0.06 to 1.01) | 36 fewer (from 0 more to 45 fewer) |
| Cardiovascular                   | MODERATE 1             | 0.92 (0.85 to 1.01)   | 30 fewer (from 4 more to 55 fewer) | MODERATE 1             | 0.93 (0.83 to 1.04)   | 17 fewer (from 10 more to 42 fewer) | -                     | NR          | NR                  |
| Hospitalization                  |                        |                       |                      |                         |                       |                        |
| All-cause                        | MODERATE 1             | 0.94 (0.86 to 1.02)   | 22 fewer (from 7 more to 52 fewer) | MODERATE 1             | 0.98 (0.93 to 1.04)   | 11 fewer (from 23 more to 40 fewer) | LOW 2                 | 0.93 (0.39 to 2.24) | 8 fewer (from 66 fewer to 154 more) |
| Heart failure                    | LOW 1 3                | 0.86 (0.56 to 1.32)   | 18 fewer (from 42 more to 38 fewer) | MODERATE 1             | 0.89 (0.80 to 0.99)   | 28 fewer (from 3 to 52 fewer) | LOW 2                 | 2.48 (0.60 to 10.28) | 23 more (from 6 fewer to 143 more) |
| Heart failure worsening          | HIGH                   | 0.85 (0.79 to 0.92)   | 51 fewer (from 27 to 71 fewer) | MODERATE 1             | 0.91 (0.84 to 0.99)   | 32 fewer (from 4 to 57 fewer) | LOW 2                 | 0.45 (0.11 to 1.86) | 16 fewer (from 26 fewer to 26 more) |
| Adverse effects                  |                        |                       |                      |                         |                       |                        |
| Leading to discontinuation       | MODERATE 1             | 1.19 (0.97 to 1.46)   | 13 more (from 2 fewer to 31 more) | MODERATE 1             | 1.17 (0.94 to 1.45)   | 11 more (from 4 fewer to 30 more) | VERY LOW 2             | 1.98 (0.37 to 10.62) | 16 more (from 11 fewer to 162 more) |
| Hypotension                      | HIGH                   | 1.60 (1.28 to 2.00)   | 30 more (from 14 to 51 more) | HIGH                   | 1.40 (1.15 to 1.72)   | 27 more (from 10 to 49 more) | VERY LOW 2             | 1.12 (0.35 to 3.53) | 7 more (from 39 fewer to 152 more) |
| Dizziness                        | MODERATE 3             | 1.39 (1.22 to 1.59)   | 51 more (from 29 to 77 more) | -                      | NR                      | NR                  | LOW 1 4                | 1.59 (1.00 to 2.52) | 142 more (from 0 to 366 more) |
| Hyperkalemia                     | HIGH                   | 1.87 (1.39 to 2.51)   | 24 more (from 11 to 42 more) | MODERATE 4             | 1.48 (1.20 to 1.83)   | 33 more (from 14 to 57 more) | -                     | NR          | NR                  |
| Serum creatinine increase        | HIGH                   | 1.46 (1.18 to 1.81)   | 27 more (from 10 to 47 more) | HIGH                   | 1.41 (1.24 to 1.60)   | 62 more (from 37 to 91 more) | -                     | NR          | NR                  |
| Cough                            | MODERATE 1             | 0.83 (0.71 to 0.97)   | 23 fewer (from 4 to 39 fewer) | -                      | NR                      | NR                  | -                     | NR          | NR                  |

ACEI: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin-2 receptor blocker, BB: beta-blocker, NR: Not reported.

1 Rated down 1 category for serious imprecision
2 Rated down 2 categories for very serious imprecision
3 Rated down 1 category for serious inconsistency
4 Rate down 1 category for suspected selective outcome reporting bias

https://doi.org/10.1371/journal.pone.0212907.t002

for adverse effects, whereas overall quality for BBs was very low to low. Table 2 lists the quality of evidence for each outcome and reasons for downgrading. We did not assess for publication bias as the number of studies for each meta-analysis was insufficient according to accepted criteria.[24]
Efficacy

Figs 3–7 illustrate the meta-analyses for efficacy outcomes, and Table 2 summarizes the absolute and relative estimates for efficacy. Post-hoc analyses pooling studies of ACEIs and ARBs are shown in Figs 8 and 9.

Adverse effects

Figs 10–15 illustrate the meta-analyses for adverse effects, and Table 2 summarizes the absolute and relative estimates for adverse effects.

Discussion

In this systematic review and meta-analysis of RCTs, higher doses of ACEIs were not statistically superior to the lower doses studied in terms of mortality or hospitalizations, but point estimates were in favour of higher doses. Higher doses of ACEIs statistically-significantly reduced the proportion of patients with episodes of worsening HF compared to lower doses. Similarly, higher doses of ARBs did not statistically reduce mortality or all-cause

| Study or Subgroup | High | Low | Risk Ratio | Risk Ratio |
|-------------------|------|-----|------------|------------|
|                  | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| 1.1.1 ACEIs       |       |       |        |                     |                      |
| van Veldhuisen 1998 |    0  |    60 |      0 | Not estimable       |                      |
| Widmisky 1995 (CASSIS) |    3  |    51 |      2 | 1.41 [0.25, 8.09]   |                      |
| Pacher 1996       |    5  |    41 |      7 | 0.73 [0.25, 2.12]   |                      |
| Clement 2000 (CHIPS) |   12 |   152 |     11 | 1.05 [0.48, 2.30]   |                      |
| Poole-Wilson 1998 (NETWORK) |   15 |   516 |     21 | 0.70 [0.37, 1.34]   |                      |
| Nanas 2000 (HEDS)  |   23  |   126 |     22 | 1.01 [0.60, 1.72]   |                      |
| Packer 1999 (ATLAS) |  666 | 1568 |    717 | 0.95 [0.87, 1.02]   |                      |
| Subtotal (95% CI) |  2514 | 2525 | 100.0%| 0.94 [0.87, 1.02]   |                      |
| Total events      |   724 |   780 |        |                     |                      |
| Heterogeneity:  |       |       |        |                     |                      |
| \( \chi^2 = 1.37, df = 5 \) (P = 0.93); \( I^2 = 0\% \) |
| Test for overall effect: \( Z = 1.52 \) (P = 0.13) |

1.1.2 ARBs

| Study or Subgroup | High | Low | Risk Ratio | Risk Ratio |
|-------------------|------|-----|------------|------------|
|                  | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Havranek 1999     |     1 |    47 |      0 | 3.06 [0.13, 73.33] |                      |
| Rieger 1999 (STRETCH) |   3  |   213 |     1  | 2.93 [0.31, 27.94] |                      |
| Konstant 2009 (HEAAL) |  635 | 1921 |    665 | 0.95 [0.87, 1.04] |                      |
| Subtotal (95% CI) |  2181 | 2169 | 100.0%| 0.96 [0.87, 1.04] |                      |
| Total events      |   639 |   666 |        |                     |                      |
| Heterogeneity:  |       |       |        |                     |                      |
| \( \chi^2 = 1.48, df = 2 \) (P = 0.49); \( I^2 = 0\% \) |
| Test for overall effect: \( Z = 1.01 \) (P = 0.31) |

1.1.3 Beta-blockers

| Study or Subgroup | High | Low | Risk Ratio | Risk Ratio |
|-------------------|------|-----|------------|------------|
|                  | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Bristow 1994      |    0  |    35 |      1 | 0.36 [0.02, 8.58]  |                      |
| Hori 2004 (MUCHA) |    1  |    77 |      2 | 0.31 [0.03, 3.27]  |                      |
| Bristow 1996 (MOCHA) |   1  |    89 |      5 | 0.19 [0.02, 1.56]  |                      |
| Subtotal (95% CI) |  201  | 168  | 100.0%| 0.25 [0.06, 1.01]  |                      |
| Total events      |    2  |    8  |        |                     |                      |
| Heterogeneity:  |       |       |        |                     |                      |
| \( \chi^2 = 0.15, df = 2 \) (P = 0.93); \( I^2 = 0\% \) |
| Test for overall effect: \( Z = 1.94 \) (P = 0.05) |

Test for subgroup differences: \( \chi^2 = 3.55, df = 2 \) (P = 0.17), \( I^2 = 43.6\% \)

Fig 3. Forest plot of risk ratios (with 95% confidence intervals) of overall mortality for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g003
Fig 4. Forest plot of risk ratios (with 95% confidence intervals) of cardiovascular mortality for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g004

Fig 5. Forest plot of risk ratios (with 95% confidence intervals) of all-cause hospitalization overall mortality for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g005
hospitalizations compared to lower doses, but point estimates were again in favor of higher doses. However, higher doses of ARBs did statistically reduced HF hospitalization and episodes of worsening HF compared to the lower doses studied. We did not find statistically-significant differences between higher and lower doses of BBs for any efficacy outcome, though results were imprecise due to few events, limiting the certainty of these findings. Higher doses increased the risk of discontinuation due to adverse events, hypotension, dizziness, and for ACEIs and ARBs, increased hyperkalemia and elevations in serum creatinine compared to lower doses.

Based on these pooled results, treating 1000 patients with higher versus lower doses of ACEIs over a mean of 28 months would result in 51 fewer patients experiencing worsening HF and 23 fewer patients experiencing cough (possibly related to the lower incidence of worsening HF). These benefits would be offset by 30–51 more patients experiencing hypotension or dizziness, and 24–27 patients having laboratory abnormalities including hyperkalemia or an increase in serum creatinine compared to lower doses.

Based on these pooled results, treating 1000 patients with higher versus lower doses of ACEIs over a mean of 28 months would result in 51 fewer patients experiencing worsening HF and 23 fewer patients experiencing cough (possibly related to the lower incidence of worsening HF). These benefits would be offset by 30–51 more patients experiencing hypotension or dizziness, and 24–27 patients having laboratory abnormalities including hyperkalemia or an increase in serum creatinine compared to lower doses.

Our results differ somewhat from those of a recent meta-analysis comparing higher versus lower doses of ACEIs/ARBs by Khan et al.[25] These authors reported that when the data from
trials evaluating ACEIs and ARBs are combined, higher doses showed a reduced risk of all-cause mortality, but no difference in hospitalizations for HF or discontinuations due to adverse effects when compared to lower doses [25]. Our meta-analysis included 4 additional trials not included in the Khan meta-analysis. In our post-hoc analysis pooling ACEIs plus ARBs for the outcome of all-cause mortality, we did not find a statistically significant difference between higher and lower doses. However, our results are quantitatively nearly identical (confidence interval 0.89–1.01 versus 0.89–1.00), and the apparent difference in the report of findings can be solely explained by dogmatic adherence to arbitrary dichotomous statistical significant thresholds.[26] Finally, for safety outcomes we used fixed-effects meta-analyses to minimize type 2 error which might account for some of the differences reported.

Applying the evidence

Given that the benefit of ACEIs, ARBs and BBs accrue over months, yet adverse effects typically occur early after starting or increasing doses, clinicians should initiate these agents at a low dose and titrate them gradually while assessing tolerability. American and Canadian HFrEF guidelines recommend this approach, with a goal of titrating the dose every 2–4 weeks as an outpatient to target doses used in the landmark placebo-controlled trials.[1],[2]
Fig 8. Forest plot of risk ratios (with 95% confidence intervals) of overall mortality (post-hoc analyses pooling studies of ACE inhibitors and angiotensin-2 receptor blockers) for higher doses versus lower doses in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g008

Fig 9. Forest plot of risk ratios (with 95% confidence intervals) of hospitalization for heart failure (post-hoc analyses pooling studies of ACE inhibitors and angiotensin-2 receptor blockers) for higher doses versus lower doses in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g009
from these guidelines, however, is a discussion of the benefits and harms of dose titration. Ideally, HF guidelines would stress the important role that shared decision-making plays in this process, particularly when a patient experiences adverse effects and must decide on the value of maintaining their current dose or continuing to up-titrate. Clinicians can use the results of this review, as summarized in Table 2, to discuss what is known about the benefits and harms of higher versus lower doses of these agents, as well areas of uncertainty about clinically-important outcomes.

**Limitations**

Our meta-analysis has limitations stemming primarily from the included trials. First, included trials did not always report all outcomes of interest, especially for BBs, limiting available data and decreasing the certainty in pooled estimates. Furthermore, trials seldom reported the definitions for adverse effects such as hypotension and increase in serum creatinine, and it is therefore difficult to put their clinical significance into context without knowledge of their severity or consequence. Second, the ranges of doses studied varied widely between trials, limiting our ability to evaluate any specific dose intensity or compare lower doses to “target doses” recommended by guidelines. Additionally, for trials evaluating more than two dosages, we selected the highest and lowest daily doses for the intervention and control group,
respectively, for our analyses. For instance, in one trial the higher-dose arm received enalapril 10 mg daily, which is a quarter of the maximum approved dose for this indication (40 mg) and half the recommended target dose, whereas in another the lower-dose arm received enalapril 20 mg daily (the recommended target dose) and the higher-dose arm received 60 mg daily (triple the target dose). Finally, we could not reliably assess for publication bias as there were too few studies (<10 trials) in each meta-analysis.[24]

**Conclusion**

Evidence comparing lower and higher doses of drugs in HFrEF is sparse and imprecise. Higher doses of ACEIs and ARBs reduce the risk of HF worsening compared to lower doses, and higher doses of ARBs also reduce the risk of HF hospitalization. Effects of higher versus lower doses of these agents on other outcomes, as well as the impact of higher versus lower doses of BBs on any efficacy outcome, remain unclear. Higher doses importantly increase the risk of hypotension and agent-specific adverse effects (e.g. hyperkalemia, cough, creatinine rise) compared to lower doses. These results reinforce recommendations to start these agents at low doses, involve patients in dose titration decisions, carefully monitor for adverse effects after dose changes, and not be averse to lowering doses when tolerability issues arise.
Higher versus lower doses in heart failure

Fig 12. Forest plot of risk ratios (with 95% confidence intervals) of dizziness for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g012

Fig 13. Forest plot of risk ratios (with 95% confidence intervals) of hyperkalemia for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

https://doi.org/10.1371/journal.pone.0212907.g013
### Supporting information

**S1 Appendix.**

(DOCX)

### Author Contributions

**Conceptualization:** James P. McCormack.
Formal analysis: Ricky D. Turgeon, Peter Loewen, James P. McCormack.

Methodology: Michael R. Kolber, Ursula Ellis.

Writing – original draft: Ricky D. Turgeon, Peter Loewen, James P. McCormack.

Writing – review & editing: Ricky D. Turgeon, Michael R. Kolber, Ursula Ellis, James P. McCormack.

References

1. Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure. Can J Cardiol. 2017; 33: 1342–1433. https://doi.org/10.1016/j.cjca.2017.08.022 PMID: 29111106

2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/American Heart Association task force on practice guidelines. Circulation. 2013; 128: 1810–1852. https://doi.org/10.1161/CIR.0b013e31829e8807 PMID: 23741057

3. Flather MD, Yusuf S, Kaber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000; 355: 1575–81. PMID: 10821360

4. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001; 134: 550–60. PMID: 11281737

5. Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract. 2008; 62: 1397–1402. https://doi.org/10.1111/j.1742-1241.2008.01806.x PMID: 18793376

6. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017; 318: 713–720. https://doi.org/10.1001/jama.2017.10565 PMID: 28829876

7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Medicine. Public Library of Science; 2009. p. e1000100. https://doi.org/10.1371/journal.pmed.1000100 PMID: 19621070

8. Higgins JPT, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. British Medical Journal Publishing Group; 2011; 343: d5928. https://doi.org/10.1136/bmj.d5928 PMID: 22008217

9. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64: 401–406. https://doi.org/10.1016/j.jclinepi.2010.07.015 PMID: 21208779

10. Packer M, Poole-Wilson PA, Armstrong PW, CleeJG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999; 100: 2312–8. PMID: 10587334

11. Widimsky J, Kremer HJ, Jerie P, Uhlír O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995; 49: 95–102. PMID: 8751029

12. Clement DL, De Buyzere M, Tomas M, Vanavermaete G. Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS). Acta Cardiol. 2000; 55: 1–7. https://doi.org/10.2143/AC.55.1.2005711 PMID: 10707752

13. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Karidis K, Tirologos A, Zobolos S, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol. 2000; 36: 2090–5. PMID: 11127445

14. Poole-Wilson PA, Bain RJ, Baksi A, Baxter RH, Been A, Benaim, et al. Clinical outcome with enalapril in symptomatic chronic heart failure; A dose comparison. Eur Heart J. 1998; 19: 481–489. https://doi.org/10.1053/euhj.1997.0839 PMID: 9568453

15. Pacher R, Stanek B, Globits S, Berger R, Hülsmann M, Wutte M, et al. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J. 1996; 17: 1223–32. PMID: 8669864
16. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man In 'T Veld AJ, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998; 32: 1811–8. PMID: 9857856

17. Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 1999; 33: 1174–81. PMID: 10193713

18. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet (London, England). 2009; 374: 1840–8. https://doi.org/10.1016/S0140-6736(09)61913-9

19. Riegger GA, Bouzo H, Petr P, Münn J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999; 100: 2224–30. PMID: 10577995

20. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994; 89: 1632–42. PMID: 7908610

21. Okamoto H, Hori M, Matsuzaki M, Tsutsui H, Yamazaki T, Nagai R, et al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. Int J Cardiol. 2013; 164: 238–44. https://doi.org/10.1016/j.ijcard.2012.11.051 PMID: 23245621

22. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996; 94: 2807–16. PMID: 8941106

23. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004; 147: 324–30. https://doi.org/10.1016/j.ahj.2003.07.023 PMID: 14760332

24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. In: Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [Internet]. 2011 [cited 25 Apr 2018]. Available: http://handbook-5-1.cochrane.org/

25. Khan MS, Fonarow GC, Ahmed A, Greene SJ, Vaduganathan M, Khan H, et al. Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis. Circ Heart Fail. 2017; 10: 1–8. https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956 PMID: 28790052

26. McCormack J, Vandermeer B, Allan GM. How confidence intervals become confusion intervals. BMC Med Res Methodol. 2013; 13: 134. https://doi.org/10.1186/1471-2288-13-134 PMID: 24172248